Targets › UL97
2 programs from 2 companies in 4 trials: 2 Phase 2, 2 Phase 3; Infectious disease, Oncology; next expected readout Jan 2027.
Open in Phaseline: the race on UL97, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Maribavir Serine/threonine-protein kinase BGLF4 inhibitor; Phosphotransferase pUL97 inhibitor | UL97 | Phase 3 | Cytomegalovirus (CMV); Hematologic Malignancy | Jan 2027 |
| Murdoch Childrens Research Institute | Ganciclovir Human herpesvirus 1 DNA polymerase inhibitor | UL97 | Phase 2 | Cytomegalovirus Viraemia | Jun 2028 |
Cytomegalovirus (CMV) (2) Cytomegalovirus Viraemia (1) Hematologic Malignancy (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.